부산대학교 도서관

INTRODUCTION Since the beginning of the pandemic, coronavirus disease-2019 (COVID-19) has progressed in very different clinical courses in children. Children were reported to have lower number of symptoms compared to [...]
Objective: There is currently no drug that is effective against the coronavirus disease-2019 (COVID-19) and no consensus was present regarding the treatment. In this cross-sectional study, we aimed to evaluate the progress of the treatment process of patients with COVID-19 since the first day of pandemic in our country and the changes in the process. Method: This single-center cross-sectional study was conducted from March 11 through November 30, 2020, in University of Health Sciences Turkey, Dr. Behcet Uz Pediatric Diseases and Surgery Training and Research Hospital, a 400-bed tertiary care hospital in Izmir, Turkey. Treatment options in all hospitalized children with COVID-19 were evaluated. Results: Evaluation of our clinical treatment algorithm from March to December, it was seen that the majority of the patients did not need any specific treatment and recovered only with supportive treatment. Because of the recommendations of the COVID-19 guidelines, no efficacy has been detected during the oseltamivir treatment and there was a significant decrease in use of azithromycin and hydroxychloroquine. Favipiravir is still the first choice of drug for patients with COVID-19. Conclusion: World Health Organization, the Infectious Diseases Society of America, and Surviving Sepsis guidelines indicate that their investigational treatments should only be used in certain clinical trial setting. Supportive care is still the main therapeutic option in COVID-19. Keywords: Antiviral drug, coronavirus disease-2019 (COVID-19), pandemic, favipiravir Amac: Gunumuzde koronavirus hastaligi-2019'a (COVID-19) karsi kanitlanmis etkili bir ilac ve de tedavi konusunda fikir birligi yoktur. Bu nedenle, kesitsel calismada, ulkemizde pandeminin ilk gununden itibaren COVID-19 hastalarinin tedavi surecinin ilerleyisini ve surecteki degisiklikleri degerlendirmeyi amacladik. Yontem: Bu tek merkezli kesitsel calisma, 11 Mart-30 Kasim 2020 tarihleri arasinda Izmir, Turkiye'de 400 yatakli ucuncu basamak bir hastane olan Saglik Bilimleri Universitesi Dr. Behcet Uz Cocuk Hastaliklari ve Cerrahi Egitim ve Arastirma Hastanesi'nde gerceklestirildi. Hastanede yatan tum COVID-19'lu cocuklarda tedavi secenekleri degerlendirildi. Bulgular: Mart-Aralik aylari arasinda klinik tedavi algoritmamiz degerlendirildiginde, hastalarin cogunlugunun herhangi bir spesifik tedaviye ihtiyac duymadigi ve sadece destek tedavisi ile iyilestigi goruldu. COVID-19 kilavuzlarinin onerileri hizla guncellenmis ve nihayetinde oseltamivir tedavisinin etkinligi olmadigi saptanmistir. Bununla birlikte pandemi ilk gunlerinden bu yana azitromisin ve hidroksiklorokin kullaniminda belirgin azalma olmustur. Favipiravir ise COVID-19 hastalari icin hala ilk ilac secimidir. Sonuc: Kilavuzlarda, tum tedavi alternatiflerinin yalnizca belirli klinik arastirma ortamlarinda kullanilmasi gerektigini gostermektedir. Destekleyici bakim, COVID-19'da hala ana tedavi secenegidir. Anahtar kelimeler: Antiviral ilac, koronavirus hastaligi-2019 (COVID-19), pandemi, favipiravir